Lupus

Massimo Radin, MD, PhD, discusses how low complement levels in the first trimester can predict disease flare in pregnant patients with systemic lupus erythematosus.

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Look back on Rheumatology Network's Congress of Clinical Rheumatology (CCR) East's conference coverage.

Anne Winkler, MD, discusses the importance of patient-reported outcome measures when treating her patients with lupus.

Anne Winkler, MD, discusses her upcoming CCR East presentation, “Targeting Lupus Nephritis.”

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 7, 2022.

The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 30, 2022.

Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2022.

Shanthini Kasturi, MD, MS, discusses the importance of patient-reported outcome measures to optimize the care of patients with systemic lupus erythematosus.

Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.

Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.

Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.

Disease flares in systemic lupus erythematosus are associated with damage. However, the impact of flares on health-related quality of life have not been analyzed.

Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.

Advice to rheumatologists in terms of staying up to date on newer treatment options entering the market for lupus.

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 26, 2021.

Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.

The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.

Iberdomide, a high-affinity cereblon modulator, works by affecting leukocyte development and autoimmunity.